Amphastar Pharma (AMPH) Misses Q4 EPS by 20c

Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.73, $0.20 worse than the analyst estimate of $0.93. Revenue for the quarter came in at $183.1 million versus the consensus estimate of $191.76 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Infleqtion raises Q2 revenue to $13.5M after contract restatement
• Bernstein SocGen Group Upgrades Whitbread PLC. (WTB:LN) (WTBCF) to Market Perform
• Dynatrace Inc. (DT) PT Raised to $65 at Citi, Adds Catalyst Watch